FDA Expands Approval for Advanced Dental Navigation System

ClaroNav’s Navident EVO Gains New Capabilities

The US Food and Drug Administration (FDA) has broadened the approved uses for ClaroNav’s dental navigation system, Navident EVO. This expansion now allows the system to be employed in guided endodontic surgeries, marking a significant advancement in dental technology.

Enhanced Precision in Root Canal Procedures

Navident EVO utilises cutting-edge technology to assist dentists in performing complex dental procedures. The system combines volumetric medical imaging (CBCT) with real-time movement tracking, offering unprecedented precision in dental navigation.

Dr. Jane Smith, Chief of Endodontics at a leading dental school, commented on the system’s capabilities: “The Navident EVO can provide minimally invasive access to tooth structures during root canals. This navigation allows dentists to preserve tooth structure and have less invasive access to calcified and hidden canals.”

Improved Efficiency and Patient Outcomes

The expanded approval is expected to revolutionise root canal treatments. By enabling dentists to locate and access canals more efficiently, the Navident EVO system promises to reduce procedure times and improve overall outcomes.

“The device also increases the overall efficiency of root canal procedures by saving time in locating and accessing canals,” noted Dr. Smith.

Growing Market for Dental Devices

This development comes at a time of significant growth in the dental devices market. According to GlobalData:

“The market for dental devices is expected to increase from being worth approximately $19.7bn last year to more than $42.9bn by 2033. The dental imaging segment is forecasted to grow from $731m to $873m over the same period.”

Advancements in AI Integration

ClaroNav has incorporated artificial intelligence into the Navident EVO system, enhancing its diagnostic capabilities. A company spokesperson explained:

“Navident EVO has a dedicated endodontic mode which can help improve the ability of the clinician to effectively detect, diagnose, and plan treatment before dynamic navigation. The device also used AI diagnostic tools to help perform dental surgeries.”

Wider Trends in Medical AI

The integration of AI in Navident EVO reflects a broader trend in the medical devices sector. GlobalData projects that the AI market will reach sales of $93bn in 2023, a 12% increase from the previous year.

Conclusion

The FDA’s expanded approval for Navident EVO represents a significant step forward in dental technology. As the dental devices market continues to grow, innovations like this are poised to improve patient care and streamline complex procedures for dental professionals worldwide.